Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BURNING ROCK BIOTECH LIMITED

(BNR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Burning Rock Biotech : First Quarter 2021 Presentation Slides

05/25/2021 | 03:55am EDT

Burning Rock Biotech Limited

BNR US Equity MSCI China index constituent since May 2021

Disclaimer

This presentation has been prepared by Burning Rock Biotech Limited (the "Company") solely for information purpose and has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of its affiliates, advisers, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its affiliates, advisers or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed.

Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company's intent, beliefs or current expectations about the future. These statements can be recognized by the use of words such as "expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident" or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances.

This presentation does not constitute an offer to sell or issue or an invitation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No part of this presentation shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

THE INFORMATION CONTAINED IN THIS DOCUMENT IS HIGHLY CONFIDENTIAL AND IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION. THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER. ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS PRESENTATION IN WHOLE OR IN PART IS UNAUTHORIZED.

By viewing, accessing or participating in this presentation, participants hereby acknowledge and agree to keep the contents of this presentation and these materials confidential. Participants agree not to remove these materials, or any materials provided in connection herewith, from the conference room where such documents are provided. Participants agree further not to photograph, copy or otherwise reproduce this presentation in any form or pass on this presentation to any other person for any purpose, during the presentation or while in the conference room. Participants must return this presentation and all other materials provided in connection herewith to the Company upon completion of the presentation. By viewing, accessing or participating in this presentation, participants agree to be bound by the foregoing limitations. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

2

What we do

China's molecular

diagnostics leader for

precision oncology

Early Detection

$29bn TAM

Therapy

Selection &

MRD

$4.5bn TAM

Notes:

3

Total addressable market size estimated per China Insights Consultancy industry report

Recap of recent progress

Early Detection

  • PRESCIENT study launched for the development of our multi-omics22-cancer test
  • Ongoing preparation work for commercialization

Therapy Selection

  • Full results of the SEQC2 study published. Liquid biopsy section published on Nature Biotechnology
  • Featured in the 2021 Consensus on Colorectal Cancer High-throughput Sequencing Molecular Diagnostics in China. Burning Rock's NGS-based bioinformatics algorithm for microsatellite instability (MSI) detection was cited as a recommended methodology

4

Early detection

Disclaimer

Burning Rock Biotech Ltd. published this content on 25 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2021 07:54:04 UTC.


ę Publicnow 2021
All news about BURNING ROCK BIOTECH LIMITED
09/14BURNING ROCK BIOTECH : and CStone Pharmaceuticals reached a strategic collaborat..
PU
09/14BURNING ROCK BIOTECH : deepens cooperation with Illumina to promote development ..
PU
09/14BURNING ROCK BIOTECH : initiates the first prospective, multi-center pan-cancer ..
PU
09/14BURNING ROCK BIOTECH : Dx Launches Magnis BR to Innovate Total Process Automatio..
PU
09/14BURNING ROCK BIOTECH : announces the completion of the Series C financing of RMB..
PU
09/14BURNING ROCK BIOTECH : China's first NGS cancer testing kit made by Burning Rock..
PU
09/14BURNING ROCK BIOTECH : Dx Honored with 2018 Guangzhou Hi-tech “Unicorn&rdq..
PU
09/14BURNING ROCK BIOTECH : Dx Certified by the Certification of ISO 13485 Quality Ma..
PU
09/14BURNING ROCK BIOTECH : and Illumina Collaborate on Molecular Diagnostics for Onc..
PU
08/31SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Tuesday
MT
More news
Analyst Recommendations on BURNING ROCK BIOTECH LIMITED
More recommendations
Financials
Sales 2021 503 M 77,8 M 77,8 M
Net income 2021 -395 M -61,1 M -61,1 M
Net cash 2021 1 443 M 223 M 223 M
P/E ratio 2021 -34,8x
Yield 2021 -
Capitalization 13 796 M 2 134 M 2 134 M
EV / Sales 2021 24,5x
EV / Sales 2022 17,9x
Nbr of Employees 938
Free-Float 72,4%
Chart BURNING ROCK BIOTECH LIMITED
Duration : Period :
Burning Rock Biotech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BURNING ROCK BIOTECH LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 131,96 CNY
Average target price 211,13 CNY
Spread / Average Target 60,0%
EPS Revisions
Managers and Directors
Yu Sheng Han Chairman & Chief Executive Officer
Leo Li Chief Financial Officer & Director
Zhi Hong Zhang Chief Technology Officer
Shao Kun Chuai Chief Operating Officer & Director
Wendy Hayes Independent Director
Sector and Competitors